Overview
ImmuCell Corporation is a U.S.-based biotechnology company primarily engaged in the development, manufacture, and sale of bovine health products that provide significant solutions to dairy and beef producers. The company, headquartered in Portland, Maine, specializes in products that improve the health and productivity of dairy and beef cattle without using antibiotics. One of ImmuCell's key projects includes the development of its flagship product, First Defense, an innovative, non-antibiotic preventative solution against scours (diarrhea) in newborn calves. This product embodies the company's commitment to delivering immediate immunity, enhancing animal health, and addressing consumer demands for antibiotic stewardship in food production. ImmuCell's focus on practical and sustainable veterinary solutions underscores its contribution to advancing animal health technology within the agricultural sector.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for ImmuCell Corporation as of June 30, 2025 is 28.27 MM.
- The operating income for ImmuCell Corporation as of June 30, 2025 is 2.14 MM.
- The net income for ImmuCell Corporation as of June 30, 2025 is 1.76 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-06-30 | 28.27 | 2.14 | 1.76 |
| 2025-03-31 | 27.30 | 0.18 | -0.27 |
| 2024-12-31 | 26.49 | -1.23 | -2.16 |
| 2024-09-30 | 23.84 | -2.74 | -3.81 |
| 2024-06-30 | 23.22 | -3.35 | -4.05 |
| 2024-03-31 | 21.28 | -3.27 | -3.90 |
| 2023-12-31 | 17.47 | -5.22 | -5.77 |
| 2023-09-30 | 16.29 | -5.79 | -6.30 |
| 2023-06-30 | 15.69 | -5.22 | -6.02 |
| 2023-03-31 | 16.01 | -4.54 | -5.32 |
| 2022-12-31 | 18.57 | -1.71 | -2.49 |
| 2022-09-30 | 20.10 | -0.52 | -0.75 |
| 2022-06-30 | 20.46 | 0.37 | 0.05 |
| 2022-03-31 | 21.14 | 1.20 | 0.88 |
| 2021-12-31 | 19.24 | 0.26 | -0.08 |
| 2021-09-30 | 17.54 | -0.52 | 0.04 |
| 2021-06-30 | 16.11 | -1.05 | -0.43 |
| 2021-03-31 | 14.54 | -1.95 | -1.34 |
| 2020-12-31 | 15.34 | -1.38 | -1.02 |
| 2020-09-30 | 15.23 | -0.99 | -1.52 |
Income Statement: EPS
- The earnings per share basic for ImmuCell Corporation as of June 30, 2025 is 0.20.
- The earnings per share diluted for ImmuCell Corporation as of June 30, 2025 is 0.21.
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-06-30 | 0.20 | 0.21 |
| 2025-03-31 | -0.03 | -0.03 |
| 2024-12-31 | -0.26 | -0.26 |
| 2024-09-30 | -0.48 | -0.49 |
| 2024-06-30 | -0.52 | -0.52 |
| 2024-03-31 | -0.50 | -0.51 |
| 2023-12-31 | -0.75 | -0.75 |
| 2023-09-30 | -0.81 | -0.81 |
| 2023-06-30 | -0.78 | -0.78 |
| 2023-03-31 | -0.69 | -0.69 |
| 2022-12-31 | -0.32 | -0.32 |
| 2022-09-30 | -0.10 | -0.10 |
| 2022-06-30 | 0.01 | 0.01 |
| 2022-03-31 | 0.11 | 0.12 |
| 2021-12-31 | -0.01 | -0.01 |
| 2021-09-30 | 0.00 | 0.01 |
| 2021-06-30 | -0.06 | -0.06 |
| 2021-03-31 | -0.19 | -0.18 |
| 2020-12-31 | -0.14 | -0.14 |
| 2020-09-30 | -0.21 | -0.21 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for ImmuCell Corporation as of June 30, 2025 is 2.53 MM.
- The cash from investing activities for ImmuCell Corporation as of June 30, 2025 is -0.74 MM.
- The cash from financing activities for ImmuCell Corporation as of June 30, 2025 is 2.88 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-06-30 | 2.53 | -0.74 | 2.88 |
| 2025-03-31 | 1.51 | -0.72 | 2.85 |
| 2024-12-31 | 0.36 | -0.46 | 2.88 |
| 2024-09-30 | -0.36 | -0.23 | 2.41 |
| 2024-06-30 | -0.23 | -0.68 | 0.78 |
| 2024-03-31 | -1.49 | -1.28 | 0.64 |
| 2023-12-31 | -4.67 | -1.89 | 1.75 |
| 2023-09-30 | -5.25 | -3.41 | 1.82 |
| 2023-06-30 | -6.00 | -3.62 | 0.03 |
| 2023-03-31 | -4.94 | -3.85 | 0.07 |
| 2022-12-31 | -1.54 | -3.96 | 1.11 |
| 2022-09-30 | 0.34 | -3.18 | 1.17 |
| 2022-06-30 | 1.86 | -3.11 | 1.60 |
| 2022-03-31 | 2.22 | -3.05 | 5.84 |
| 2021-12-31 | 0.95 | -1.60 | 3.88 |
| 2021-09-30 | 0.52 | -0.14 | 4.79 |
| 2021-06-30 | -0.40 | -0.94 | 4.44 |
| 2021-03-31 | -0.17 | -2.63 | 1.69 |
| 2020-12-31 | 1.32 | -2.57 | 1.91 |
| 2020-09-30 | 1.11 | 0.88 | 0.98 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/book for ImmuCell Corporation as of June 30, 2025 is 2.17.
- The p/tbv for ImmuCell Corporation as of June 30, 2025 is 2.17.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-06-30 | 2.17 | 2.17 | |
| 2025-03-31 | 1.69 | 1.70 | |
| 2024-12-31 | 1.63 | 1.63 | |
| 2024-09-30 | -6.87 | 1.19 | 1.19 |
| 2024-06-30 | -9.57 | 1.51 | 1.52 |
| 2024-03-31 | 1.58 | 1.59 | |
| 2023-12-31 | -6.26 | 1.52 | 1.52 |
| 2023-09-30 | -6.87 | 1.54 | 1.55 |
| 2023-06-30 | -7.26 | 1.37 | 1.38 |
| 2023-03-31 | 0.00 | 0.00 | |
| 2022-12-31 | -62.86 | 1.48 | 1.48 |
| 2022-09-30 | 1.82 | 1.83 | |
| 2022-06-30 | 2.01 | 2.02 | |
| 2022-03-31 | -962.77 | 2.31 | 2.31 |
| 2021-12-31 | 1,701.34 | 1.91 | 1.92 |
| 2021-09-30 | -166.87 | 2.25 | 2.26 |
| 2021-06-30 | |||
| 2021-03-31 | -46.36 | 2.23 | 2.25 |
| 2020-12-31 | -60.82 | 2.20 | 2.21 |
| 2020-09-30 | -40.82 | 2.22 | 2.23 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for ImmuCell Corporation as of June 30, 2025 is -0.00.
- The ebit (3y)/ev for ImmuCell Corporation as of June 30, 2025 is -0.05.
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-06-30 | -0.00 | -0.05 |
| 2025-03-31 | -0.04 | -0.07 |
| 2024-12-31 | -0.08 | -0.08 |
| 2024-09-30 | -0.11 | -0.10 |
| 2024-06-30 | -0.08 | -0.06 |
| 2024-03-31 | -0.11 | -0.05 |
| 2023-12-31 | -0.12 | -0.05 |
| 2023-09-30 | -0.12 | -0.04 |
| 2023-06-30 | -0.11 | -0.04 |
| 2023-03-31 | -0.00 | -0.00 |
| 2022-12-31 | -0.02 | -0.02 |
| 2022-09-30 | 0.00 | -0.01 |
| 2022-06-30 | 0.02 | -0.01 |
| 2022-03-31 | -0.00 | -0.01 |
| 2021-12-31 | 0.00 | -0.01 |
| 2021-09-30 | -0.01 | -0.02 |
| 2021-06-30 | ||
| 2021-03-31 | -0.02 | -0.02 |
| 2020-12-31 | -0.02 | -0.02 |
| 2020-09-30 | -0.02 | -0.02 |
Management Effectiveness
- The roa for ImmuCell Corporation as of June 30, 2025 is -0.01.
- The roe for ImmuCell Corporation as of June 30, 2025 is -0.01.
- The roic for ImmuCell Corporation as of June 30, 2025 is -0.01.
- The croic for ImmuCell Corporation as of June 30, 2025 is 0.08.
- The ocroic for ImmuCell Corporation as of June 30, 2025 is 0.03.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-06-30 | -0.01 | -0.01 | -0.01 | 0.08 | 0.03 |
| 2025-03-31 | -0.05 | -0.09 | -0.05 | 0.04 | -0.01 |
| 2024-12-31 | -0.09 | -0.15 | -0.09 | 0.04 | -0.01 |
| 2024-09-30 | -0.09 | -0.16 | -0.10 | -0.00 | -0.01 |
| 2024-06-30 | -0.09 | -0.14 | -0.10 | -0.05 | -0.04 |
| 2024-03-31 | -0.18 | -0.14 | -0.16 | -0.12 | |
| 2023-12-31 | -0.14 | -0.20 | -0.14 | -0.16 | -0.12 |
| 2023-09-30 | -0.13 | -0.18 | -0.14 | -0.23 | -0.14 |
| 2023-06-30 | -0.12 | -0.16 | -0.14 | -0.23 | -0.14 |
| 2023-03-31 | -0.05 | -0.07 | -0.00 | -0.00 | -0.00 |
| 2022-12-31 | -0.02 | -0.02 | -0.02 | -0.04 | 0.01 |
| 2022-09-30 | 0.01 | 0.01 | -0.02 | -0.04 | 0.01 |
| 2022-06-30 | 0.03 | 0.03 | 0.01 | 0.01 | 0.04 |
| 2022-03-31 | -0.00 | -0.00 | 0.03 | 0.15 | 0.06 |
| 2021-12-31 | 0.00 | 0.00 | -0.00 | 0.08 | 0.01 |
| 2021-09-30 | -0.01 | -0.02 | 0.00 | 0.12 | -0.01 |
| 2021-06-30 | -0.01 | -0.02 | -0.01 | 0.07 | -0.01 |
| 2021-03-31 | -0.03 | -0.05 | -0.03 | -0.03 | -0.00 |
| 2020-12-31 | -0.03 | -0.04 | -0.03 | 0.02 | 0.03 |
| 2020-09-30 | -0.04 | -0.05 | -0.04 | 0.08 | 0.03 |
Gross Margins
- The gross margin for ImmuCell Corporation as of June 30, 2025 is 0.34.
- The net margin for ImmuCell Corporation as of June 30, 2025 is -0.01.
- The operating margin for ImmuCell Corporation as of June 30, 2025 is 0.01.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-06-30 | 0.34 | -0.01 | 0.01 |
| 2025-03-31 | 0.30 | -0.08 | -0.06 |
| 2024-12-31 | 0.29 | -0.16 | -0.11 |
| 2024-09-30 | 0.28 | -0.17 | -0.14 |
| 2024-06-30 | 0.30 | -0.18 | -0.15 |
| 2024-03-31 | 0.22 | -0.33 | -0.33 |
| 2023-12-31 | 0.22 | -0.39 | -0.39 |
| 2023-09-30 | 0.23 | -0.38 | -0.37 |
| 2023-06-30 | 0.31 | -0.38 | -0.41 |
| 2023-03-31 | 0.41 | -0.33 | -0.31 |
| 2022-12-31 | 0.46 | -0.04 | -0.03 |
| 2022-09-30 | 0.48 | -0.04 | -0.03 |
| 2022-06-30 | 0.48 | 0.01 | 0.03 |
| 2022-03-31 | 0.45 | 0.05 | 0.07 |
| 2021-12-31 | 0.44 | -0.00 | 0.01 |
| 2021-09-30 | 0.44 | 0.00 | -0.03 |
| 2021-06-30 | 0.44 | -0.03 | -0.06 |
| 2021-03-31 | 0.43 | -0.09 | -0.13 |
| 2020-12-31 | 0.45 | -0.07 | -0.09 |
| 2020-09-30 | 0.46 | -0.10 | -0.06 |
Identifiers and Descriptors
| Central Index Key (CIK) | 811641 |
Industry Groups
| SIC 2835 - In Vitro and In Vivo Diagnostic Substances |
